@article {Wasfi:2011:1088-5412:453,
title = "Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast",
journal = "Allergy and Asthma Proceedings",
parent_itemid = "infobike://ocean/aap",
publishercode ="ocean",
year = "2011",
volume = "32",
number = "6",
publication date ="2011-11-01T00:00:00",
pages = "453-459",
itemtype = "ARTICLE",
issn = "1088-5412",
eissn = "1539-6304",
url = "https://www.ingentaconnect.com/content/ocean/aap/2011/00000032/00000006/art00014",
doi = "doi:10.2500/aap.2011.32.3482",
keyword = "randomized trial, montelukast, children, prevention, exercise-induced bronchoconstriction, Asthma, crossover study, pediatric, FEV1, placebo",
author = "Wasfi, Yasmine S. and Kemp, James P. and Villar{\’a}n, C{\’e}sar and Massaad, Rachid and Xin, Wenjing and Smugar, Steven S. and Knorr, Barbara A. and Philip, George",
abstract = "Single-dose montelukast attenuates exercise-induced bronchoconstriction (EIB) in adults within 2 hours postdose and lasting through 24 hours. This study evaluated the onset and duration of EIB attenuation in children after a single dose of montelukast. A randomized, double-blind, placebo-controlled,
two-period crossover study was performed. Patients (n = 66) aged 414 years, with preexercise forced expiratory volume in 1 second of (FEV1) 70% predicted and maximum percentage fall in FEV1 of 20% at two screening exercise challenges were eligible. Patients
were to receive single-dose montelukast (4 or 5 mg) or placebo before performing standardized exercise challenges at 2 and 24 hours postdose. A 3- to-7-day washout separated the two crossover periods. The primary end point was maximum percentage fall in FEV1 after exercise challenge
2 hours postdose. Secondary end points included maximum percentage fall in FEV1 after the 24-hour postdose challenge; each of the following at 2 and 24 hours postdosemaximum percentage fall in FEV1 categorized as 20%; area under the
curve (AUC) during 60 minutes postchallenge; time to recovery of FEV1 to within 5% of preexercise baseline; and need for rescue medication. The mean maximum percentage fall in FEV1 after the 2-hour postdose exercise challenge was significantly attenuated after single-dose
montelukast compared with placebo (15.35% versus 20.00%; p = 0.020). Montelukast was also significantly more effective than placebo for maximum percentage fall after the 24-hour challenge (12.92% versus 17.25%; p = 0.005), the categorized maximum percent fall in FEV1 at 2 hours
(p = 0.034), and AUC at 2 hours (p = 0.022) and 24 hours (p = 0.013). Single-dose montelukast provided rapid and sustained EIB attenuation in children. Clinicaltrials.gov
identifier: NCT00534976
",
}